Patients with hepatocellular carcinoma (HCC) comply with an advanced disease and are not
eligible for radical therapy. In this distressed scenario new treatment options hold great …

We hypothesized that sorafenib plus transarterial chemoembolization (TACE) would confer
survival benefits over sorafenib alone for advanced hepatocellular carcinoma (aHCC). We …

Combined immune checkpoint inhibitors (ICIs) along with tyrosine kinase inhibitors (TKIs)
and locoregional therapies have been used increasingly to treat hepatocellular carcinoma …

Biomarkers for predicting the treatment efficacy of immune checkpoint inhibitor (ICI)-based
therapy in patients with unresectable hepatocellular carcinoma (uHCC) are crucial. Previous …

Background: Sorafenib is the standard of care, first line treatment for advanced HCC. This
study aims to evaluate real-life efficacy and safety of sorafenib in Egyptian patients with …

Background Although sorafenib is considered standard therapy for advanced hepatocellular
carcinoma (HCC), actual treatments vary. We evaluated the effects of different treatment …

Six dogs with massive hepatocellular carcinoma that was not amenable to surgery were
treated by oral administration of single-agent toceranib at a dose of 2.0–3.0 mg/kg every …

Sorafenib has been recommended as a new palliative therapy for advanced hepatocellular
carcinoma (HCC). However, the clinical outcome of patients receiving sorafenib therapy …

Sorafenib is the recommended first‐line treatment option for patients with advanced
hepatocellular carcinoma (HCC). Hepatitis C virus (HCV)‐related advanced HCC (HCV …

Objective Though synergy of sorafenib and transarterial chemoembolization (TACE) in
hepatocellular carcinoma (HCC) is well discussed in previous reports, association of lipiodol …